Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:6.3.2.19 (
ubiquitin-protein ligase
)
799
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Antizyme is a polyamine-induced cellular protein that binds to ornithine decarboxylase (ODC), and targets it to rapid ubiquitin-independent degradation by the 26S proteasome. However, the metabolic fate of
antizyme
is not clear. We have tested the stability of
antizyme
in mammalian cells. In contrast with previous studies demonstrating stability in vitro in a reticulocyte lysate-based degradation system, in cells
antizyme
is rapidly degraded and this degradation is inhibited by specific proteasome inhibitors. While the degradation of ODC is stimulated by the presence of cotransfected
antizyme
, degradation of
antizyme
seems to be independent of ODC, suggesting that
antizyme
degradation does not occur while presenting ODC to the 26S proteasome. Interestingly, both species of
antizyme
, which represent initiation at two in-frame initiation codons, are rapidly degraded. The degradation of both
antizyme
proteins is inhibited in ts20 cells containing a thermosensitive
ubiquitin-activating enzyme
, E1. Therefore we conclude that in contrast with ubiquitin-independent degradation of ODC, degradation of
antizyme
requires a functional ubiquitin system.
...
PMID:Ornithine decarboxylase-antizyme is rapidly degraded through a mechanism that requires functional ubiquitin-dependent proteolytic activity. 1185 66